Discontinued — last reported Q2 '17
Thermo Fisher Scientific Long-Term Debt - Fair Value increased by 2.1% to $33.08B in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 0.1%, from $33.04B to $33.08B. Over 4 years (FY 2020 to FY 2024), Long-Term Debt - Fair Value shows an upward trend with a 3.7% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
An increase relative to book value may indicate rising interest rates or changes in credit risk, while a decrease may suggest favorable refinancing opportunities.
This represents the estimated market value of the company's long-term debt obligations if they were to be settled or tra...
Standard across large-cap pharmaceutical firms, often compared against total debt to assess interest rate sensitivity.
long_term_debt_fair_value| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $20.77B | $23.50B | $36.05B | $32.25B | $27.34B | $25.11B | $30.29B | $31.64B | $30.11B | $30.78B | $32.27B | $32.66B | $32.06B | $33.04B | $28.53B | $31.19B | $32.40B | $33.08B |
| QoQ Change | — | +13.1% | +53.4% | -10.5% | -15.2% | -8.2% | +20.6% | +4.5% | -4.8% | +2.2% | +4.8% | +1.2% | -1.9% | +3.1% | -13.7% | +9.3% | +3.9% | +2.1% |
| YoY Change | — | — | — | — | +31.6% | +6.9% | -16.0% | -1.9% | +10.1% | +22.6% | +6.5% | +3.2% | +6.5% | +7.3% | -11.6% | -4.5% | +1.1% | +0.1% |
We use cookies for analytics. See our Privacy and Cookie Policy.